PhRMA submission to the 2019 National Trade Estimate Report urges action to protect U.S. biopharmaceutical innovation
By Douglas Petersen | November 2, 2018
International trade is critical to delivering life-saving and life-enhancing medicines in the global economy, which is why PhRMA addresses several discriminatory foreign government practices in...
Read More
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
By Holly Campbell | July 16, 2018
Today, PhRMA submitted comprehensive comments to the Department of Health and Human Services (HHS) request for information (RFI), HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs....
Read More
To continue to drive the innovation economy and exports, American biopharmaceutical sector depends on fair trade agreements
By Jay Taylor | May 10, 2018
May is World Trade Month, when we celebrate the many American companies exporting products around the world, and growing opportunities here in the U.S.
Read More
Poll respondents appreciate economic benefits of innovation and call for more protections
By Mark Grayson | July 11, 2017
Increasingly, economists and international organizations are recognizing innovation as one of the most important drivers of economic and social progress and stability. In fact, a report released...
Read More
As U.S. looks to modernize NAFTA, strong enforcement of existing obligations should be a top priority
By Mark Grayson | June 13, 2017
Yesterday, PhRMA filed comments on negotiating objectives for the modernization of the North American Free Trade Agreement (NAFTA). The Administration’s review of our trading relationship with...
Read More
Foreign government price setting by any name harms innovation and access to medicines
By Kevin Haninger | June 6, 2017
In an effort to contain health care spending, some foreign governments mandate prices for innovative medicines at levels below the value they provide to patients, health care systems, and the...
Read More
Administration’s Special 301 Report highlights deteriorating global environment for biopharmaceutical innovation
By Jay Taylor | May 23, 2017
In the latest publication of its annual Special 301 Report, the Office of the U.S. Trade Representative (USTR) brings renewed attention to intellectual property (IP) and market access challenges...
Read More
Compulsory licensing: A misused and abused international trade law
By Jay Taylor | May 16, 2017
To maintain our position as the world’s top biopharmaceutical innovator, the U.S. biopharmaceutical industry needs predictable and reliable intellectual property protections. Compulsory licensing...
Read More
It’s no coincidence that America leads the world in the discovery and development of new lifesaving medicines. U.S. biopharmaceutical innovators invest $60 billion in R&D annually – more than any...
Read More
ICYMI: Ubl weighs in on how fair trade protects US biopharmaceutical innovation
By Mark Grayson | May 5, 2017
America’s biopharmaceutical leadership is a result of a robust medical innovation ecosystem driven by several factors: a free-market economy that rewards innovation, strong intellectual property...
Read More
Medicare Monday (100)
340B Spotlight (37)
Cost & Consequence (0)
